Bioanalytical Method Validation of an RP-HPLC Method for Determination of Rifampicin in Liver Perfusion Studies
- 1 August 2021
- journal article
- research article
- Published by Elsevier in Current Pharmaceutical Analysis
- Vol. 17 (7) , 919-925
Abstract
Background: The number of validated quantification methods for rifampicin, a prototypical Oatp inhibitor, in biological rat samples was limited. Objective: This study was conducted to validate a modified reversed-phase liquid chromatographic method for the determination of rifampicin in rat liver tissue according to the current ICH M10 Bioanalytical Method Validation Draft Guideline (2019) for application to samples of in situ rat liver perfusion studies. Methods: Liver tissue samples were obtained from recirculatory in situ rat liver perfusion studies. The analysis was performed on a C18 column with a mobile phase composed of 0.05 M phosphate buffer (pH 4.58): acetonitrile (55:45, v/v). The assay was validated for selectivity, calibration curve and range, matrix effect, carry-over, accuracy and precision, reinjection reproducibility, and stability. Results: he method was considered selective and stable, without having carry-over and matrix effects. The calibration curve was linear (R2: 0.9983) within the calibration range (0.5-60 ppm). Accuracy and precision values fulfilled the required limits. Liver concentrations of rifampicin in liver tissue, obtained after 60 min perfusion with 10 μM and 50 μM of rifampicin, were 45.1 ± 11.2 and 313.4 ± 84.4 μM, respectively. Conclusion: The bioanalytical method validation was completed and the method was successfully applied for the determination of rifampicin in rat liver tissue.Keywords
Funding Information
- Scientific and Technological Research Council of Turkey, TUBITAK (2211-A, 2214-A)
- Hacettepe University (TSA-2019-17756)
This publication has 20 references indexed in Scilit:
- Hepatic Basolateral Efflux Contributes Significantly to Rosuvastatin Disposition II: Characterization of Hepatic Elimination by Basolateral, Biliary, and Metabolic Clearance Pathways in Rat Isolated Perfused LiverThe Journal of Pharmacology and Experimental Therapeutics, 2013
- Evaluation of Oatp and Mrp2 Activities in Hepatobiliary Excretion Using Newly Developed Positron Emission Tomography Tracer [11C]Dehydropravastatin in RatsThe Journal of Pharmacology and Experimental Therapeutics, 2013
- Disposition Kinetics of Diclofenac in the Dual Perfused Rat LiverJournal of Pharmaceutical Sciences, 2013
- Recent advances in 2D and 3D in vitro systems using primary hepatocytes, alternative hepatocyte sources and non-parenchymal liver cells and their use in investigating mechanisms of hepatotoxicity, cell signaling and ADMEArchives of Toxicology, 2013
- Simultaneous Assessment of Uptake and Metabolism in Rat Hepatocytes: A Comprehensive Mechanistic ModelThe Journal of Pharmacology and Experimental Therapeutics, 2012
- Understanding the interplay of drug transporters involved in the disposition of rosuvastatin in the isolated perfused rat liver using a physiologically-based pharmacokinetic modelXenobiotica, 2011
- Multiple Transporters Affect the Disposition of Atorvastatin and Its Two Active Hydroxy Metabolites: Application of in Vitro and ex Situ SystemsThe Journal of Pharmacology and Experimental Therapeutics, 2006
- Ex Situ Inhibition of Hepatic Uptake and Efflux Significantly Changes Metabolism: Hepatic Enzyme-Transporter InterplayThe Journal of Pharmacology and Experimental Therapeutics, 2004
- Organic anion transporting polypeptides of the OATP/ SLC21 family: phylogenetic classification as OATP/ SLCO superfamily, new nomenclature and molecular/functional propertiesPflügers Archiv - European Journal of Physiology, 2004
- Rifamycin SV and rifampicin exhibit differential inhibition of the hepatic rat organic anion transporting polypeptides, Oatp1 and Oatp2Hepatology, 2000